33 results about "Hl60 cells" patented technology

The invention relates to the field of genetic engineering, in particular to a novel fungal immunomodulatory protein FIP-NHA with antineoplastic activity and a gene thereof. The fungal immunomodulatory protein FIP-NHA according to the invention has an amino acid sequence as shown in SEQ ID NO. 1, and the gene fip-nha for coding the fungal immunomodulatory protein has a nucleotide sequence as shownin SEQ ID NO. 2. The fungal immunomodulatory protein FIP-NHA provided by the invention has the effects on promoting splenic lymphocyte division, increasing synthesis of interleukin 2, and obviously inhibiting proliferation of three tumor cells including hepatoma cell HepG2, gastric cancer cell MGC823 and leukemia cell HL60, therefore, the fungal immunomodulatory protein FIP-NHA as a novel antineoplastic biological agent can be widely used in the fields of health products and biological medicines.

The invention relates to the fields of marine organism and medical technology, and provides an aaptamine alkaloid compound which is obtained by extraction, separation and purification from marine Aaptos aaptos produced in sea areas nearby the Paracel Islands, wherein the chemical structure of the alkaloid compound is as shown in the formula (I) (in the specification). In-vitro activity tests prove that the alkaloid compound has remarkable inhibitory activity on various different tumor cells such as human acute leukemic cells HL60, human chronic leukemic cells K562, human breast cancer cells MCF-7, human nasopharyngeal carcinoma cells KB, human liver cancer cells Hep G2 and human colon cancer cells HT-29, and the alkaloid compound can be used for preparing anti-tumor medicines.

The invention provides 2,4-diarylamine pyrimidine derivatives containing hydroxamic acid fragments shown in formulas I and II. 2,4-diarylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the remarkable anti-proliferative effect is achieved for tumor cells (a human lung adenocarcinoma cell line H1975 and an overexpression EGFR human epidermal carcinoma cell line A431) related to EGFR tyrosine kinase activity on the cellular level, and a human cervical carcinoma cell line Hela, a human oral epidermoid carcinoma cell line KB, a human promyelocytic acute leukemia cell line HL60, a human hepatoma cell line HepG2, a human colon cancer cell line SW620 and other tumor cells related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

An oral biology model which comprises biofilm, oral epithelial tissue and a suspension of neutrophil-like cells in media is disclosed. The biofilm, which comprises oral bacteria, is produced by culturing oral bacteria on a solid substrate. The oral epithelial tissue may be gingival epithelial tissue to model the gingival crevice or buccal epithelial tissue to model the oral check. The suspension of neutrophil-like cells in media comprises neutrophil-like cells that are differentiated HL60 cells induced to a neutrophil-like phenotype by treatment with retinoic acid. Methods of using the oral biology model to test and compare compounds and formulations or to screen compounds and formulations for their effect on release of inflammatory signals, their effect on biofilm and oral bacteria and / or their effect on the cellular components are disclosed.

The invention discloses 14 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters shown in the general formula I. In the general formula I, AA represents L-Ser residue, L-Glu (OBzl) residue, L-Phe residue, L-Val residue, L-Arg residue, L-Tyr residue, L-Ala residue, L-Trp residue, L-Asn residue, L-Met residue, L-Ile residue, Gly residue, L-Asp (OBzl) residue or L-Leu residue. The invention discloses a preparation method of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, discloses HT-29, K562, A549 and HL60 tumor cell growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, further discloses S180-loading mice tumor growth inhibition effects of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters, and also discloses use of the 3H-imidazo[4,5-c]pyridine-6-formyl-amido acid benzyl esters as antitumor drugs.

The invention relates to the field of biotechnology, aiming at providing sTRAIL protein and a primer thereof in crassostrea rivularis for resisting human tumor HL60. The protein is provided with an amino acid sequence as shown in SEQ ID NO: 2; gene for encoding the protein is provided with an nucleotide sequence as shown in SEQ ID NO: 1. The invention is also applied to expand oligonucleotide primer of the gene of the protein as shown in a right claim 2. The sTRAIL protein product developed by gene engineering technique of the invention has the advantages of mass destruction to HL60 tumor cell, high specificity, good security, mass production and easy storage.

The invention discloses targeting antineoplastic fusion protein LPO. An artificially synthesized target gene segment LHRH-PEA wiped membrane peptide-ONC (LPO for short) is inserted in PET28a plasmids, and the fusion protein is expressed after the LPO inserted the plasmids are conveyed in escherichia coli BL21(DE3). Experiments prove that the fusion protein LPO has obvious inhibiting effect to tumor cell lines with LHRH receptors such as colon cancer LOVO cells, lung cancer A549 cells, oral cancer KB cells and prostatic cancer PC-3M cells rather than lymphoma Hut 102 and leukemia HL60 without LHRH receptors, and has targeting specificity, and is safe and reliable.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The invention discloses a GM-CSF target-direction drug liposome and preparing method of anti acute leukemia myelomatosis, which is composed of cytokine guiding matter with initiative target-tropism connecting to the surface of liposome and anti acute leukemia myelomatosis drug in liposome. The external model MTT of the invention experiments and checks the toxic effect on the cell of acute leukemia myelomatosis cell strain HL60 and the effect on cell death. The method improves the curative effect, which reduces the cost.